全文获取类型
收费全文 | 3227413篇 |
免费 | 252884篇 |
国内免费 | 5626篇 |
专业分类
耳鼻咽喉 | 47337篇 |
儿科学 | 102631篇 |
妇产科学 | 89576篇 |
基础医学 | 460008篇 |
口腔科学 | 92956篇 |
临床医学 | 289967篇 |
内科学 | 627433篇 |
皮肤病学 | 66711篇 |
神经病学 | 265691篇 |
特种医学 | 128314篇 |
外国民族医学 | 1170篇 |
外科学 | 490357篇 |
综合类 | 74210篇 |
现状与发展 | 2篇 |
一般理论 | 1202篇 |
预防医学 | 255409篇 |
眼科学 | 76030篇 |
药学 | 243252篇 |
5篇 | |
中国医学 | 6006篇 |
肿瘤学 | 167656篇 |
出版年
2018年 | 32080篇 |
2016年 | 27270篇 |
2015年 | 30994篇 |
2014年 | 44204篇 |
2013年 | 67596篇 |
2012年 | 91588篇 |
2011年 | 97082篇 |
2010年 | 57124篇 |
2009年 | 54461篇 |
2008年 | 92505篇 |
2007年 | 99230篇 |
2006年 | 100361篇 |
2005年 | 98009篇 |
2004年 | 94543篇 |
2003年 | 91175篇 |
2002年 | 90208篇 |
2001年 | 146348篇 |
2000年 | 151226篇 |
1999年 | 128155篇 |
1998年 | 37338篇 |
1997年 | 33627篇 |
1996年 | 33577篇 |
1995年 | 32339篇 |
1994年 | 30433篇 |
1993年 | 28290篇 |
1992年 | 103701篇 |
1991年 | 100903篇 |
1990年 | 98179篇 |
1989年 | 94891篇 |
1988年 | 88162篇 |
1987年 | 86733篇 |
1986年 | 82404篇 |
1985年 | 78910篇 |
1984年 | 59645篇 |
1983年 | 51098篇 |
1982年 | 31000篇 |
1981年 | 27552篇 |
1980年 | 25844篇 |
1979年 | 56311篇 |
1978年 | 39813篇 |
1977年 | 33719篇 |
1976年 | 31879篇 |
1975年 | 34087篇 |
1974年 | 41461篇 |
1973年 | 39506篇 |
1972年 | 37349篇 |
1971年 | 34577篇 |
1970年 | 32461篇 |
1969年 | 30460篇 |
1968年 | 28200篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
901.
P F Plouin D L Clement H Boccalon J Dormandy I Durand-Zaleski G Fowkes L Norgren T Brown 《International angiology》2003,22(4):333-339
Atherosclerotic renal artery stenosis (ARAS) may cause hypertension, progressive renal failure, and recurrent pulmonary edema. It typically occurs in high risk patients with coexistent vascular disease elsewhere. Most patients with ARAS are likely to die from coronary heart disease or stroke before end-stage renal failure occurs. Recent controlled trials have shown that most patients undergoing angioplasty to treat renovascular hypertension still need antihypertensive agents 6 or 12 months after the procedure. Nevertheless, the number of antihypertensive agents required to control blood pressure adequately is lower following angioplasty than for medication alone. Trials assessing the value of revascularization for preserving renal function or preventing clinical events are only in the early recruitment phase. Revascularization should be undertaken in patients with ARAS and resistant hypertension or heart failure, and probably in those with rapidly deteriorating renal function or with an increase in plasma creatinine levels during angiotensin-converting enzyme inhibition. With or without revascularization, medical therapy using antihypertensive, hypolipidemic and antiplatelet agents is necessary in almost all cases. 相似文献
902.
903.
M. Naumann A. Albanese F. Heinen G. Molenaers M. Relja 《European journal of neurology》2006,13(S4):35-40
Botulinum toxin serotype A (BoNT-A) has long heritage of use leading to confidence in its safety and efficacy. The application of BoNT-A does not lead to persistent histological changes in the nerve terminal or the target muscle. Clinical trials defined the safety and tolerability profile of BoNT-A across common therapeutic indications and showed an incidence of adverse events of approximately 25% in the BoNT-A-treated group compared with 15% in the control group. Focal weakness was the only adverse event to occur more often following BoNT-A treatment. Long-term BoNT-A administration has been assessed in various treatment settings, with the level and duration of BoNT-A efficacy response being maintained over repeated rounds of injection with no major safety concerns. The treatment of children with cerebral palsy often require long-term, repeated, multimuscle BoNT-A injections that lead to the administration of comparably higher toxin doses. Despite the high total body doses used, their distribution over multiple muscles and injection sites means that systemic side effects are rare. Recent formulation changes have reduced the incidence of antibody development following treatment with BOTOX® . These findings show long-term BoNT-A treatment to be both safe and efficacious for a wide variety of indications. 相似文献
904.
905.
906.
Is atrial fibrillation an inflammatory disorder? 总被引:2,自引:0,他引:2
I read with great interest the excellent review on the influenceof inflammation in the pathogenesis of atrial fibrillation (AF)by Boos 相似文献
907.
908.
909.
Kevin L Taylor Rhonda K Oates Ron Grane Douglas W Leaman Ernest C Borden Daniel J Lindner 《Journal of interferon & cytokine research》2006,26(5):353-361
Interferon-alpha (IFN-alpha) has proved effective in the treatment of hemangiomas, hemangioblastomas, and Kaposi's sarcoma. To investigate the ability of IFNs to inhibit angiosarcoma, we used two transformed murine endothelial cell lines that form angiosarcomas in vivo. SVR and MS1-VEGF cell lines express oncogenic H-ras or vascular endothelial growth factor (VEGF), respectively. IFN-alpha1,8, which is active against murine and human cells, inhibited SVR and MS1-VEGF proliferation in vitro by 40% at 10(3) U/mL (p = 0.028). In vivo, IFN-alpha1,8 inhibited SVR tumor volume by 71% (p = 0.047) and MS1-VEGF volume by 79% (p = 0.003). Tumor-induced angiogenesis was decreased in SVR tumors by 52% (p = 0.005) and in MS1-VEGF tumors by 58% (p = 0.001). Sera from IFN-alpha1,8-treated mice bearing either SVR or MS1-VEGF tumors demonstrated a 5-fold increase in IP-10/CXCL10 (p = 0.001), an IFN-induced antiangiogenic protein. Both recombinant IP-10 and IFN-alpha1,8 inhibited human umbilical vein endothelial cell (HUVEC) vessel formation in the fibrin gel assay, a three-dimensional culture model of angiogenesis, by 56% at 25 ng/mL and 50% at 1.2 ng/mL, respectively (p < 0.001). An IP-10 blocking antibody restored vessel formation to 80% of untreated controls (p = 0.001). Given the magnitude of the in vivo response, these data suggested that the antitumor effects of IFN-alpha1,8 were likely mediated through angiogenesis inhibition rather than solely by direct inhibition of tumor cell proliferation. 相似文献
910.
Â. C. Volpini M. J. Marques S. Lopes dos Santos G. L. Machado-Coelho W. Mayrink A. J. Romanha 《Clinical microbiology and infection》2006,12(8):815-818
This study examined the ability of PCR to amplify Leishmania DNA, stored on Giemsa-stained slides, from American cutaneous leishmaniasis (ACL) patients. In total, 475 slides stored for up to 36 years were obtained from an outpatient clinic in a Brazilian ACL-endemic region, and Leishmania DNA was amplified from 395 (83.2%) of the DNA samples using primers specific for the minicircle kinetoplast DNA. Restriction fragment length polymorphism analysis of these amplicons demonstrated that Leishmania (Viannia) braziliensis was the only species present in these samples. The results demonstrated that archived Giemsa-stained slides can provide a Leishmania DNA source for performing clinical and epidemiological studies of leishmaniasis. 相似文献